Topic: Avandia
Avandia, or rosiglitazone maleate, is a prescription drug used to control blood sugar in adults with type 2 diabetes. A 2007 study indicated that Avandia significantly increases the risk of heart attack. The bulk of the lawsuits against GlaxoSmithKline were settled prior ...
The side effects of Avandia on the heart have been the topic of criticisms aimed at the U.S. Food and Drug Administration (FDA) for a decade. A cardiologist at the Cleveland Clinic found a 43% higher occurrence of heart attacks among patients ...
For those millions of people who live with Diabetes each day, they know that it can be a sinister opponent which is hard to keep control of if not properly treated. The study was looking to have 16,000 patients, but by some ...
In September 2010, the U.S. Food and Drug Administration (FDA) announced new restrictions on Avandia, a diabetes drug , in response to new evidence the drug raises the risk of heart attacks and strokes. Back in 2007 , the FDA wanted black-box ...
The troubled diabetes drug Avandia (rosiglitazone) stay available on the market with Restrictions In a very widely-anticipated ruling, a panel of experts decided not to advise that the FDA pull GlaxoSmithKline's blockbuster diabetes drug Avandia off of the market in the United ...
Patient safety will remain at risk until big pharma's top executives are brought to book for their companies' actions, says Paul Thacker . The latest case concerns GlaxoSmithKline's Avandia (rosiglitazone), an anti-diabetes drug linked to heart attacks. Last month, the European Medicines ...
According to documents obtained by the New York Times, for 11 years SmithKline Beecham hid secret test data showing that its diabetes drug, Avandia, posed a greater heart risk and was no more effective than Actos, made by Takeda, a competitor. "And ...
The United States and Europe are both greatly restricting use of the diabetes drug Avandia, culminating several years of concern that the drug increases the risk of heart problems. The European Medicines Agency (EMA) is taking Avandia off the market, while the ...
U.S. health regulators dealt a major blow to the controversial diabetes pill Avandia Thursday, requiring doctors and patients to sign consent forms before starting a prescription of the drug. At the same time, European regulators ordered it off the market. The split ...
The European Medicines Agency (EMA) said Avandia's benefits no longer outweighed its risks. The EMA committee said marketing of the product should be suspended and no further prescriptions issued while the suspension is in place. GlaxoSmithKline, which produces the drug containing rosiglitazone, ...
